Connect with us

Press Release

Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold

Published

on

–News Direct–

Affiliate Avenue, the newsdirect.com channel for compelling affiliate marketing content, has recently posted an article by Jeannine Mancini of Benzinga Money entitled:

Can You Guess How Many Americans Successfully Retire With $1 Million Saved? The Percentage May Shock You

Mancini reviews the shockingly low percentage of Americans who have amassed the recommended minimum retirement nest egg to live a comfortable post-employment lifestyle.

The article provides a free retirement quiz and offers to connect readers with vetted fiduciary financial advisors via a free tool from SmartAsset.

Contact Details

News Direct

Media at News Direct

success@newsdirect.com

Company Website

https://newsdirect.com/affiliate-avenue

View source version on newsdirect.com: https://newsdirect.com/news/benzinga-money-article-discusses-how-to-become-part-of-the-12-of-retirees-who-have-achieved-the-recommended-550-000-minimum-retirement-savings-threshold-244408969

AffiliateAvenue

comtex tracking

COMTEX_453213209/2655/2024-06-01T14:28:09

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (CMS” or the Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication.

 

Impressive phase III trial data in AD

Its Priority Review is expected to accelerate its NDA approval

 

Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas.

 

Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.

  1. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).
  2. Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.

 

Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.

 

Building an integrated AD solution,

strengthening Dermavons leadership in dermatology

 

AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.

 

Dermavon has developed a comprehensive treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.

 

Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health.

 

More Information About Ruxolitinib Phosphate Cream

Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].

 

The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).

 

Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.

 

 

About CMS

 

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

1. China Insights Consultancy’s industrial report

2. The U.S. FDA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib

3. The EMA approval information can be found on the Incyte official website, as follows:

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar

 

 

CMS Disclaimer and Forward-Looking Statements

 

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Groups market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

 

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Vaal Bulk Bags Highlights Role of Recycled FIBCs in South Africa’s Bulk Packaging Sector

Published

on

Vaal Bulk Bags, based in the Vaal region of Gauteng, outlines how new and recycled Flexible Intermediate Bulk Containers (FIBCs) are supporting South Africa’s industrial and agricultural supply chains. The company supplies new, refurbished and bespoke bulk bags to sectors including agriculture, construction, food, recycling and waste management. By purchasing used bags, refurbishing suitable units and supporting polypropylene recycling at end of life, Vaal Bulk Bags contributes to more circular packaging practices while maintaining a focus on quality, reliability and operational efficiency for high-volume material handling.

Vereeniging, Gauteng, South Africa, 24th Feb 2026 – Vereeniging-based bulk packaging specialist Vaal Bulk Bags is drawing attention to the growing role of recycled and refurbished bulk bags in South Africa’s industrial and agricultural value chains, as local businesses seek cost-effective, durable and more sustainable alternatives to conventional packaging and waste-disposal practices.vaalbulkbags.co+2

The company, located in the Vaal region of Gauteng, supplies a broad selection of Flexible Intermediate Bulk Containers (FIBCs) and related big bags to sectors ranging from agriculture and construction to food, recycling, retail, skip and waste management. Operating from a warehouse environment geared for immediate dispatch, Vaal Bulk Bags maintains stock of popular FIBC sizes and configurations, enabling rapid response to recurring bulk handling requirements across these industries.farm+3

Vaal Bulk Bags’ offering spans both new and second-hand bags, including recycled and reconditioned options that have been inspected and prepared for reuse. Each used bag undergoes a quality-check process designed to ensure that it is safe and ready for further service, reflecting an operational focus on consistency and reliability. The company also purchases used bags from customers, diverting them from landfill and channeling them back into productive use where appropriate. This buyback and refurbishment activity positions bulk bags not only as a logistics solution, but also as a mechanism for reducing packaging waste and extending material lifecycles.vereeniging.infoisinfo.co+2

On the new bag side of its operations, Vaal Bulk Bags manufactures big bags to international quality standards, including ISO 9001. New FIBCs are produced and supplied in a variety of sizes, strengths and fabric specifications, with options that include different coatings, ventilation properties, filling spouts and lifting arrangements. Configurations such as valve tops, skirt tops and open tops are offered to match distinct filling, discharge and handling requirements in the field. The company’s product range extends from standard builders’ bags up to bags of approximately 2 metres in height, supporting varied payload and volumetric needs in construction, agriculture, waste and other bulk-handling environments.vaalbulkbags.co+2

In addition to standard stock items, Vaal Bulk Bags makes provision for bespoke manufacturing where applications fall outside typical specifications. When an end user requires a specific size, design or combination of features that is not readily available from the warehouse, the company can design and manufacture a batch of bags tailored to those parameters. This capability enables more precise alignment between bag design and on-site operating conditions, such as equipment constraints, material characteristics or stacking and transport requirements.vereeniging.infoisinfo.co+1

The business has, over time, accumulated experience across a spectrum of industries, including agricultural producers, building and civil contractors, food-related operations, recycling and waste firms, and retail-linked warehousing and distribution activities. Bulk bags supplied into these environments are used for materials such as sand, grain, fertilizers, construction aggregates, waste streams and various industrial commodities that must be stored or transported in large, manageable units. Due to their structure and materials, these bags can typically be used multiple times before replacement, contributing to lower packaging costs per cycle and reduced demand for one-way containers.agrifoodsa+3

Environmental considerations are a recurring theme in the way bulk bags are employed and recovered across the market. By promoting reuse and offering recycled and second-hand bags that have been checked for continued suitability, Vaal Bulk Bags participates in a broader shift toward resource efficiency and landfill diversion within the packaging segment. Bulk bags that have reached the end of their usable life can often be directed to appropriate polypropylene recycling channels, where material is processed for alternative applications. This progression—from new manufacture and multiple reuses to eventual material recycling—illustrates how FIBCs can fit into more circular packaging models in the South African context.vaalbulkbags.co+2

From a logistical standpoint, bulk bags offer several operational efficiencies for users. Their collapsible nature reduces storage space when bags are empty, in contrast with rigid containers that occupy a fixed footprint regardless of load status. Standardized footprints and lifting configurations facilitate handling with forklifts, cranes and other equipment commonly found on farms, construction sites and industrial facilities. As a result, organizations can consolidate loose materials into fewer, larger units, improving stacking, transport utilization and on-site housekeeping.agrifoodsa+1

The Vaal region, where Vaal Bulk Bags is based, functions as an industrial corridor linking various manufacturing, processing and logistics operations in Gauteng and surrounding areas. Locating stocking and refurbishment activities within this geography enables the company to respond quickly to demand spikes and maintain short delivery routes to many regional customers. For industries with continuous material flows—such as mining-linked suppliers, agricultural cooperatives or recycling operations—access to ready-to-ship inventory of bulk bags can help limit disruptions related to packaging availability.farm+2

Vaal Bulk Bags reports that it places emphasis on the quality of both its products and its customer support. Staff members are available to assist organizations that are uncertain about which bag configurations may be most suitable for their specific use cases, including guidance on size selection, fabric options and handling characteristics. This consultative element plays a role when businesses evaluate whether standard stock items will be adequate, or whether a bespoke design might better address operational or safety considerations.vaalbulkbags.co+2

The company’s activities align with broader trends within South Africa’s flexible packaging and bulk handling segments, where FIBCs and similar solutions are increasingly adopted to manage large volumes of materials in a controlled, repeatable manner. As sectors such as construction, agriculture, mining and manufacturing continue to demand packaging that is both robust and adaptable, bulk bags have become a familiar sight across worksites, warehouses and transport networks. Within this environment, Vaal Bulk Bags continues to focus on supplying new and recycled bags, maintaining inventory and offering bespoke manufacturing to support the evolving requirements of these industries.digitaljournal+4

For further information, Vaal Bulk Bags can be contacted via its website at https://vaal-bulk-bags.co.za/.[vaalbulkbags.co]​

Media Contact

Organization: Vaal bulk bags

Contact Person: Roman

Website: https://vaal-bulk-bags.co.za/

Email: Send Email

Contact Number: +27765988308

Address:Factory Road Olive Branch Park

Address 2: Ext. 2 Unit 1 Peacehaven

City: Vereeniging

State: Gauteng

Country:South Africa

Release id:41842

The post Vaal Bulk Bags Highlights Role of Recycled FIBCs in South Africa’s Bulk Packaging Sector appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Kingbull launches the Ranger, a long-range dual-suspension fat-tire e-bike starting in the $700 range

Published

on

Kingbull today announced the launch of its latest retro-style electric bike, Ranger, a motorcycle-inspired model engineered to deliver high torque performance, long-range capability, and all-terrain stability in a single platform. Designed for riders who demand power, comfort, and visual distinction, the new release reflects Kingbull’s continued focus on performance-driven urban and recreational mobility.

Built around a reinforced carbon steel (alloy) frame, the bike balances structural durability with riding stability. Weighing 86 lbs, the chassis is optimized to support a maximum payload of 350 lbs, making it suitable for a wide range of riders and use cases—from daily commuting to extended weekend rides.

At the core of the system is a 750W rear hub motor with 1500W peak output, delivering 80Nm of torque. This configuration enables confident acceleration and hill-climbing performance, including gradients up to 30 degrees under proper riding conditions. Riders can engage power through a twist throttle for direct, motorcycle-style control or use pedal assist for a more traditional e-bike experience.

Range performance is equally robust. Under optimal conditions, the bike delivers up to 80 miles on a single charge, positioning it competitively within the long-range segment of the market. This extended range supports commuting, leisure riding, and longer-distance exploration without frequent recharging interruptions.

Ride comfort is reinforced through a Dual Shock Absorption System that integrates a suspension front fork with a spring rear shock absorber. This dual-suspension setup enhances vibration damping across uneven pavement, gravel paths, and mixed-terrain environments. Paired with CST BFT tires, the bike maintains traction and stability across diverse riding surfaces.

Stopping power is managed by hydraulic disc brakes equipped with 180mm rotors, providing consistent and responsive braking performance. This braking configuration is engineered to deliver controlled deceleration under varying load conditions and terrain demands.

Drivetrain functionality is supported by a Shimano 7-speed transmission system, allowing riders to adjust cadence and gearing efficiently across flat stretches and incline segments. A centrally mounted 3.5-inch display presents essential ride data, including speed, battery status, and assist level, ensuring clear visibility while in motion.

In terms of rider setup, the bike arrives 85% pre-assembled, reducing installation complexity and enabling faster deployment upon delivery. This streamlined assembly process aligns with Kingbull’s goal of improving user accessibility while maintaining mechanical reliability.

Visually, the model adopts a retro motorcycle-style aesthetic, combining classic design cues with contemporary electric mobility engineering. The result is a platform that delivers both visual impact and measurable performance capability.

As demand continues to grow for high-power, long-range electric bikes that blend design character with mechanical substance, Kingbull’s latest release reinforces the brand’s commitment to delivering durable, torque-rich, and comfort-oriented riding solutions.

About KingbullBike

KingbullBike is an electric bicycle manufacturer offering models designed for commuting, recreational riding, and off-road use. The company focuses on product engineering, durability, and alignment with recognized safety standards, including model-level testing practices commonly used in the e-bike category. KingbullBike provides product documentation to support customers and partners evaluating safety and compliance requirements in different markets.

For additional information regarding specifications, availability, or dealer inquiries, please visit Kingbull’s official website.

Social Media:

Instagram: https://www.instagram.com/kingbullbike/
Facebook: https://www.facebook.com/KingbullBikes
YouTube: https://www.youtube.com/@kingbullbike
X: https://x.com/Kingbullbike
TikTok: https://www.tiktok.com/@kingbullbike

 

Media Contact

Organization: Kingbull Technology, INC.

Contact Person: Ethan Doo

Website: https://www.kingbullbike.com/

Email:
ethan.doo@kingbullbike.com

Contact Number: +12135884335

Address:5101 Santa Monica Boulevard

City: Los Angeles

State: CA

Country:United States

Release id:41373

The post Kingbull launches the Ranger, a long-range dual-suspension fat-tire e-bike starting in the $700 range appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST